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thickness while least for the width.The maximum width is 
overestimated especially when the parametrial invasion is 
present at BT with CT based contouring. 
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Purpose/Objective: To compare the maximum target 
dimensions and image quality between magnetic resonance 
imaging (MRI), transrectal ultrasound (TRUS) and computed 
tomography (CT) in image guided adaptive brachytherapy 
(IGABT) of locally advanced cervical cancer 
Materials and Methods: All patients with locally advanced 
cervical cancer treated with radiochemotherapy and IGABT 
between 09/2012-05/2013 were included in this study. T2-
weighted MRI (1.5 tesla), TRUS and CT were performed 
before (MRIpreBT, TRUSpreBT) and / or after (MRIBT, TRUSBT and 
CTBT) insertion of the applicator. 3D TRUS image acquisition 
was done with a customized US stepper device and software. 
The target was defined on 3D image sequences acquired with 
different imaging modalities by one blinded observer, in 
accordance to the GEC-ESTRO recommendations for MRI-
based target volume delineation, as the complete cervical 
mass including the tumour, any suspicious areas of 
parametrial involvement and the normal cervical stroma. 
Maximum target width and thickness were measured on 
transversal planes. Image quality was classified using the 
following scoring system: Grade 0: not depicted, Grade 1: 
inability to discriminate, margin not recognizable, Grade 2: 
fair discrimination, margin indistinct, Grade 3: excellent 
discrimination, margin distinct. Descriptive statistics, mean 
differences between the groups, with MRIBT as reference, and 
a paired t-test were calculated.  
Results: Images from 21 patients (FIGO IB: 3, IIB: 11, IIIB: 5, 
IVB: 2) were available for analysis. The mean difference in 
maximum target width of TRUSBT, TRUSpreBT, MRIpreBT, CTBT to 
MRIBT was 0.5mm ±5.5 (n.s.), -1.7mm ±5.7 (n.s.), 0.0mm ±5.7 
(n.s.) and 12.9mm ±6.1 (p < 0.001) (figure 1). The mean 
difference in maximum target thickness of TRUSBT, TRUSpreBT, 
MRIpreBT, CTBT to MRIBT was -3.5mm ±5.5 (p=0.012), -7.6mm 
±4.3 (p <0.001), 0.5mm ±6.4 (n.s.) and 11.8mm ±6.3 (p < 
0.001). Mean scores of image quality of the target volume 
was 2.9 for TRUSpreBT, 2.3 for TRUSBT, 2.9 for MRIpreBT, 2.7 for 
MRIBT and 2.1 for CTBT. 
Conclusions: TRUS seems to be superior to CT for assessment 
of the target volume in IGABT of cervical cancer as it yields 
systematically smaller deviations from the gold standard T2-
weighted MRI, with reasonable image quality. Differences of 
TRUS target thickness might likely be related to differences 
in image slice orientation and compression of the target 
volume by the TRUS probe before insertion of the 
brachytherapy applicator.  
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Purpose/Objective: To assess the use of brachytherapy with 
or without external beam radiation in medically inoperable 
stage I endometrial adenocarcinoma in the United States and 
to determine the effect of brachytherapy on overall survival 
(OS) and cause specific survival (CSS). 
Materials and Methods: Data between 1998 and 2011 from 
the National Cancer Institute's Surveillance, Epidemiology and 
End Results (SEER) database were analyzed. Coarsened exact 
matching was used to adjust for differences in age, grade and 
year of diagnosis between patients who received 
brachytherapy and those who did not. Prognostic factors 
affecting OS and CSS including age, grade, race, marital 
status, metropolitan residential area, and year of diagnosis 
were evaluated using Kaplan Meier product-limit method and 
Cox proportional hazards regression model. Cumulative 
incidence was calculated using a competing risks model. 
Results: A total of 460 patients with inoperable stage I 
endometrial adenocarcinoma treated with radiation therapy 
were identified. Radiation consisted of either external beam 
radiation (n=260) or brachytherapy with or without external 
beam radiation (n=200). The only factor associated with 
brachytherapy use was younger patient age (median age: 72 
vs. 76, p=0.001). Median survival for all patients was 40 
months. Patients who received brachytherapy had a higher 3 
year OS (OS: 60% vs. 47%, p<0.001) and CSS (CSS: 82% vs. 74%, 
p=0.032) compared to those who did not. On multivariate 
analysis, brachytherapy use was independently associated 
with an improved OS (OS: hazard ratio [HR]=0.68, 95% 
confidence interval [CI]: 0.52 – 0.87) and CSS (CSS: HR=0.61, 
95% CI: 0.39 – 0.93). In the matched cohort of patients 
(n=260), the OS benefit associated with brachytherapy 
remained significant on multivariate analysis (OS: HR=0.65, 
95% CI: 0.47 - 0.88). Brachytherapy was also associated with 
a lower 2 year cumulative incidence of cancer specific death 
(19% vs. 13%). 
Conclusions: Brachytherapy is independently associated with 
an improved OS. It should be considered as part of the 
treatment regimen for all stage I inoperable endometrial 
patients undergoing radiation.  
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